{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Prime Medicine, Inc.
Prime Medicine, Inc. Experiences Evaluation Revision Amidst Strong Market Performance
Prime Medicine, Inc., a small-cap pharmaceutical company, has recently adjusted its evaluation amid market dynamics. The stock is currently priced at $5.65, with a notable annual return of 55.22%. Technical indicators show a mixed outlook, reflecting the company's volatility and resilience in a competitive sector.
Is Prime Medicine, Inc. technically bullish or bearish?
As of October 10, 2025, Prime Medicine, Inc. shows a mildly bullish trend with mixed technical indicators, including bullish moving averages and MACD, but bearish RSI readings, while outperforming the S&P 500 significantly over the past month and year-to-date.
Is Prime Medicine, Inc. technically bullish or bearish?
As of October 10, 2025, the trend is mildly bullish due to positive moving averages and Bollinger Bands, but caution is advised due to bearish RSI readings and some weakness indicated by the MACD.
Is Prime Medicine, Inc. technically bullish or bearish?
As of October 10, 2025, Prime Medicine, Inc. shows a mildly bullish trend with strong moving averages and Bollinger Bands, despite bearish RSI readings, and has outperformed the S&P 500 significantly with a 46.02% return over the past month and 94.52% year-to-date.
Prime Medicine Soars 9.88% to Day High of $6.85 Amid Strong Intraday Performance
Prime Medicine, Inc. has experienced notable stock performance, with significant gains over various timeframes, including a year-to-date return of 120.89%. Despite challenges such as negative EBITDA and a substantial net loss, the company reported a remarkable increase in net sales, attracting considerable institutional interest.
Prime Medicine, Inc. Hits New 52-Week High of $6.94
Prime Medicine, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low. With a market capitalization of USD 693 million, the company faces challenges, including a negative return on equity and a lack of dividend yield, as it navigates the competitive biotechnology sector.
Prime Medicine, Inc. Hits New 52-Week High of $6.92
Prime Medicine, Inc. has achieved a new 52-week high, recovering significantly from its previous low. However, its one-year performance remains negative, contrasting with broader market gains. The company faces financial challenges, including a negative return on equity and high price-to-book ratio, while lacking a dividend.
Prime Medicine, Inc. Hits New 52-Week High of $5.82
Prime Medicine, Inc. has achieved a new 52-week high, reflecting a significant recovery from its previous low. However, the company's one-year performance shows a decline, contrasting with broader market gains. Operating in a challenging environment, it faces negative returns and high valuation metrics, while not offering dividends.
Prime Medicine, Inc. Hits New 52-Week High of $5.63
Prime Medicine, Inc. has achieved a new 52-week high of USD 5.63, marking a recovery from a previous low of USD 1.11. Despite this milestone, the company's one-year performance is down 27.6%, and it faces financial challenges, including a negative return on equity and high debt-to-equity ratio.
Prime Medicine, Inc. Hits New 52-Week High of $5.43
Prime Medicine, Inc. has achieved a new 52-week high of USD 5.43, recovering from a previous low of USD 1.11. Despite this milestone, the company's one-year performance remains negative, and it faces challenges with significant debt and a lack of dividends, reflecting its position in the biotechnology sector.
Prime Medicine Stock Soars 8.02%, Hits Intraday High of $5.43
Prime Medicine, Inc. has seen notable stock activity, with significant gains over the past week and month, despite a year-long underperformance. The company reported substantial growth in net sales, but faces challenges with negative EBITDA and considerable operating cash flow losses, attracting investor interest in its fundamentals.
Prime Medicine, Inc. Hits New 52-Week High of $5.20
Prime Medicine, Inc. has achieved a new 52-week high of USD 5.20, rebounding from a previous low of USD 1.11. Despite this milestone, the company has experienced a one-year decline of 36.33%. With a market cap of approximately USD 693 million, it operates at a loss and does not pay dividends.
Prime Medicine, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Prime Medicine, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has experienced significant stock price fluctuations, currently at $4.89. The company has shown strong performance over various timeframes, outperforming the S&P 500, with notable returns of 67.47% year-to-date, reflecting its volatility and market dynamics.
Is Prime Medicine, Inc. technically bullish or bearish?
As of September 11, 2025, Prime Medicine, Inc. is in a bullish trend, supported by positive indicators like a bullish MACD and Bollinger Bands, despite a bearish weekly RSI, and has outperformed the S&P 500 with a 1-week return of 25.49% and a 1-month return of 46.29%.
Is Prime Medicine, Inc. technically bullish or bearish?
As of May 9, 2024, the market trend is mildly bearish, influenced by daily moving averages and weekly RSI, though weekly MACD and Bollinger Bands suggest some bullish conditions, leading to a cautious overall sentiment.
What does Prime Medicine, Inc. do?
Prime Medicine, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $52 million as of March 2025. It has a market cap of $212.04 million and key metrics indicating significant financial challenges.
How big is Prime Medicine, Inc.?
As of Jun 18, Prime Medicine, Inc. has a market capitalization of 212.04 million, with net sales of 3.84 million and a net profit of -202.02 million over the last four quarters. Shareholder's funds are 153.15 million, and total assets are 490.14 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
